Piramal spends £55m to bolster its UK manufacturing presence
The investment covers two expansions to accommodate several pipeline products moving to commercial scale
CDMO Piramal Pharma Solutions has laid out plans to increase its UK presence by investing approximately £55 million at its Grangemouth (Scotland) and Morpeth (England) facilities.
The company has said it will be expanding antibody-drug conjugate (ADC) capabilities at Grangemouth and upgrading the API infrastructure at Morpeth.
Not only will this investment enhance Piramal's s drug development and manufacturing capabilities in the UK, it will also increase new employment opportunities for technical and operational staff.
Specifically, two new ADC manufacturing suites, which the company expects will be up and running by Q3 2023, will be added to the existing three to significantly expand Piramal's ADC capacity at this site.
The building has been designed to accommodate further expansion, with planned future phases that include a new sterile fill/finish suite dedicated to ADCs and two additional large-scale manufacturing suites capable of handling increased batch sizes.
The company says it is also constructing a new customer experience center for clients who are visiting the site during development and/or manufacturing activities. Ground preparation and piling works are alreadt well under way.
The new facility will be fully supported by analytical laboratories (QC, cell-based assay and ELISA, GMP), warehousing, and administrative offices, all housed in a purpose-built facility.
Piramal Pharma Solutions' CEO Peter DeYoung cited demand for commercial ADCs as well as a "strong pipeline for clinical materials" as the main drivers behind doubling the company's ADC production capacity at Grangemouth.
The price tag for the Grangemouth expansion, which is being built on a 5-acre brownfield plot less than 100 m from the existing site, accounts for £45 million, including £2.4-million grant from Scottish Enterprise, Scotland's national economic development agency, as well as client co-funding.
The approximately £10 million investment in API capabilities at the company's Morpeth site, will include new equipment, infrastructure, and utility systems to meet increased market demand from global API customers.
At the same time, by replacing obsolete equipment with new, energy-efficient alternatives, Piramal will also improve its carbon footprint.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance